JK

Jigna Ketanbhai Ambasana

Active Director Director DIN 10619622
DIN 10619622 First appointment May 2024
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Jigna Ketanbhai Ambasana

Data last updated:

Jigna Ketanbhai Ambasana is a Director at Medifusion Healthcare Private Limited (since 2024).

DIN 10619622
Primary Designation Director
First Appointment 07 May 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director07 May 20242024Active

Directorship timeline

Open interactive timeline →
Medifusion Healthcare Private Limited
Premium access

Shareholding and investment profile for Jigna Ketanbhai Ambasana

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Jigna Ketanbhai Ambasana

Jigna Ketanbhai Ambasana currently holds 1 directorship: Medifusion Healthcare Private Limited (Director, since 07 May 2024).

Jigna Ketanbhai Ambasana was first appointed on 07 May 2024 as Director at Medifusion Healthcare Private Limited.

The current boards of Jigna Ketanbhai Ambasana's companies include Parag Shrikrishna Dikshit (Medifusion Healthcare Private Limited), Pravinkumar Babu Shetty (Medifusion Healthcare Private Limited), Suryakant Niranjan Chiplunkar (Medifusion Healthcare Private Limited), Vijay Sadashiv Patil (Medifusion Healthcare Private Limited), Vishal Devidas Chandekar (Medifusion Healthcare Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available